Call for Abstracts
Period for Abstract Submission
Wednesday, December 5th, 2018 until Thursday,
January 31st, 2019 noon, JST
February 7th, 2019 noon, JST
Abstract submission has been closed.
Abstract Submission Process
1. Presentation Style and Language
All abstracts for General Presentation and Symposium must be written in English.
|Lecture form||Title||Presentation Language|
|Symposium 1||Current status and future perspective of AI-based diagnosis of arrhythmias||
|Symposium 2||Automaticity of the heart: New insight||
|Symposium 3||Current topics of Inherited arrhythmias||
|Symposium 4||HFpEF-related atrial fibrillation -Significance of sinus rhythm||
|Symposium 5||Silent atrial fibrillation: epidemiology, diagnosis, and treatment||
|Symposium 6||Impact of beta blockades in the treatment of arrhythmias: from bench to bedside||
|Symposium 7||An alarming growth of AF population – How to use oral anticoagulants safely||
|Symposium 8||Recent advantages in balloon-based atrial fibrillation ablation||
|Symposium 9||Novel strategy of catheter ablation for persistent atrial fibrillation-Ｈow to optimize extra-PV substrate modification||
|Symposium 10||Latest technology for scar-related reentrant VTs- Searching for the Optimal Endpoint||
|Symposium 11||How to ablate idiopathic ventricular arrhythmias difficult to map and access the origins of arrhythmias||
|Symposium 12||Emerging 3-D mapping systems for diagnosi and management of arrhythmias||
|Symposium 13||Long term efficacy and safety in His-bundle pacing||
|Symposium 14||Unresolved issues of cardiac device and lead extraction||
|Symposium 15||Clinical impact and indication of novel devices and surgical procedures for left atrial appendage closure||
2. Body of the Abstract
There is a 250 word limit to the body of your abstract (Please do not include author name(s) and organizational affiliation(s)). It may include one diagram, which should be in GIF or JPEG format and of 300 KB or less in size. The diagram can be in either landscape or portrait orientation and will be reduced to about 75 mm x 45 mm when printed. Please note that even if you submit a color diagram, it will be printed in black and white. In case the abstract includes a diagram, the body of the abstract should be up to 150 words.
3. Registration ID and Password
Upon your abstract submission, you should “create new account” at first. With this ID and your own password you chose when you first registered as a user, you will be able to log in to your personal abstract submission page and edit or amend your abstract at any time up to the deadline of abstract submission.
※You will be responsible for safekeeping of your password and other confidential information.
4. Presentation Language for General Presentation
Please select your presentation language, among “English”, “Japanese or English” and “Japanese preferred” at the time of registration. Note that all slides and posters must be in English only.
5. Presentation Style for General Presentation
Please select your presentation style, either “oral or poster” or “poster preferred” at the time of registration.
6. Type of Presentation Language
The presentation language will, in principle, be as per your indication. The presentation style (oral or poster), however, will be determined by the congress secretariat with regard to the schedule.
7. Publication of Accepted Abstracts
Accepted abstracts, not only the body of abstract but also abstract title, author's name and organizational affiliation will be published exactly as you registered online. We recommend you to carefully read the instructions as you fill out required information.
To submit an abstract, please sing in form the “Abstract Submission” button at the bottom of this page and follow the instructions. The registration period starts from Wednesday, December 5th, 2018 until Thursday, January 31st, 2019 noon, JST.
The category of your abstract is required to process your application. Please choose from the following list the number that best describes the subject of your abstract.
Basic /Translational Science
|1||Ion Channels and Transporters: Molecular Structure, Function, and Regulation||6||Computer Modeling / Simulation|
|2||Ion Channels and Transporters: Micro Anatomy and Pathology||7||Intact Heart Electrophysiology (includes Pharmacology and Optical Mapping)|
|3||Genomics: Bench||8||Whole Animal Electrophysiology and Pharmacology (includes Neurohumoral Modulation)|
|5||Cell Physiology, Pharmacology, and Signaling|
Provocative Cases (Case reports)
|10||Atrial fibrillation / Atrial flutter||15||Tachycardia Devices|
|11||SVT / AVNRT / WPW / AT||16||Device Implantation / Extraction|
|12||VT / VF / VPC||17||Pediatric / Adult Congenital Heart Disease|
Cardiovascular Implantable Electronic Devices
|20||Device Technology||22||Indications and Complications|
|24||Device Technology||26||Indications and Complications|
Heart Failure Management
|28||Device Technology||29||Indications and Complications|
Diagnostic Devices & Sensors
|32||Device Technology||33||Indications and Complications|
Leads & Electrodes
|37||Extraction / Removal||40||Others|
Monitoring & Outcomes
|41||Monitoring & Follow-up||42||Outcomes, Quality Measures & Complications|
Catheter/ Surgical Ablation
SVT / AVNRT / WPW / AT
|43||Clinical Studies / Outcomes||47||Ablation|
|44||Experimental Methods||48||Clinical Studies|
|45||Quality Measures & Complications||49||Drug Therapy|
|46||Mapping & Imaging||50||Others|
Atrial Fibrillation & Atrial Flutter
|51||Clinical Studies / Outcomes||55||Ablation|
|52||Experimental Methods||56||Clinical Studies|
|53||Quality Measures & Complications||57||Others|
|54||Mapping & Imaging||58||Drug Therapy|
|59||Clinical Studies / Outcomes||63||Ablation|
|60||Experimental Methods||64||Clinical Studies|
|61||Quality Measures & Complications||65||Others|
|62||Mapping & Imaging||66||Drug Therapy|
Sudden Cardiac Death
|67||Risk Assessment (SAECG/TWA, HRV, QT interval etc. )||69||Prevention / Treatment|
|68||Epidemiology / Physiology||70||Others|
Syncope & Bradycardia
|71||Mechanism / Diagnosis||74||Clinical Studies|
|72||Prevention / Treatment||75||Others|
|73||Drug Therapy and Devices|
|76||Atrial fibrillation / Atrial flutter||79||Heart failure|
|77||SVT / AVNRT / WPW / AT||80||Others|
|78||VT / VF / VPC|
|81||Brugada syndrome, Early repolarization syndrome, and Idiopathic VF||82||LQT syndrome, ARVC, and others|
Cardiac Resynchronization Therapy
Non-CRT Devices for Heart Failure
Heart Failure Management
Pediatric / Adult Congenital Heart Disease
|93||Pediatric Cardiology||96||Training and Education|
|94||Adult Congenital Heart Disease||97||Others|
|98||Reimbursement, Regulation, and Health policy|
Young Investigator Award (YIA)
Please indicate whether or not you would like your abstract to be forwarded to the YIA selection process. The final nominees will be selected based on peer-review recommendation. Those finalists will make a presentation for the final selection at the YIA session during the congress.
Eligibility for YIA
- To qualify for the YIA, candidates must be primary authors who are aged under 40 as of July 1, 2019.
- Please note that you have ever received the YIA in the past, you are not able to apply for the YIA.
- If your abstract is nominated for the YIA, you must submit a paper to the "Journal of Arrhythmia (English)".
- The final selection of submitted abstracts will be done by the congress presidents, based on the reviews of the Scientific Program Committee.
- Notification of acceptance will be sent in the middle of April to the email address that was provided during the registration process. We will also post the results on our website.
- Please note that we may not be able to fulfill all requests with regard to venue and/or program.
- If your symposium proposal is not accepted, the abstract will be forwarded for consideration as a general presentation, only in case you have chosen to.
Page to access the Abstract Registration page
If you have any queries about the submission process or acceptance result, please email the Congress Secretariat (E-mail: email@example.com). Please make sure to indicate your registration number in your inquiry.)